MXPA02006146A - Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos. - Google Patents

Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.

Info

Publication number
MXPA02006146A
MXPA02006146A MXPA02006146A MXPA02006146A MXPA02006146A MX PA02006146 A MXPA02006146 A MX PA02006146A MX PA02006146 A MXPA02006146 A MX PA02006146A MX PA02006146 A MXPA02006146 A MX PA02006146A MX PA02006146 A MXPA02006146 A MX PA02006146A
Authority
MX
Mexico
Prior art keywords
gepirone
psychological disorders
methods
bioactive metabolites
treating psychological
Prior art date
Application number
MXPA02006146A
Other languages
English (en)
Spanish (es)
Inventor
Joseph P Yevich
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Publication of MXPA02006146A publication Critical patent/MXPA02006146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA02006146A 1999-12-20 2000-12-18 Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos. MXPA02006146A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (1)

Publication Number Publication Date
MXPA02006146A true MXPA02006146A (es) 2004-08-23

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006146A MXPA02006146A (es) 1999-12-20 2000-12-18 Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.

Country Status (20)

Country Link
US (1) US6534507B1 (hu)
EP (1) EP1242061B1 (hu)
JP (1) JP4236407B2 (hu)
KR (1) KR100602976B1 (hu)
CN (1) CN1411375A (hu)
AT (1) ATE294572T1 (hu)
AU (1) AU776409B2 (hu)
CA (1) CA2395458C (hu)
CZ (1) CZ300429B6 (hu)
DE (1) DE60019968T2 (hu)
ES (1) ES2241683T3 (hu)
HU (1) HU228963B1 (hu)
IL (2) IL150222A0 (hu)
MX (1) MXPA02006146A (hu)
NO (1) NO323304B1 (hu)
NZ (1) NZ519554A (hu)
PL (1) PL200378B1 (hu)
PT (1) PT1242061E (hu)
RU (1) RU2282448C2 (hu)
WO (1) WO2001045687A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
PL374000A1 (en) 2002-08-12 2005-09-19 Bristol-Myers Squibb Company Improved process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
TW200521125A (en) * 2003-11-18 2005-07-01 Bristol Myers Squibb Co Continuous process for producing hydroxyazapirones by oxidation
MX2007005368A (es) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc Formulacion con liberacion prolongada de dosis alta de gepirona.
JP2011519953A (ja) * 2008-05-08 2011-07-14 ファーブル−クレイマー・ファーマシューティカルズ，インコーポレイテッド 注意欠陥障害および性機能不全の治療のための３−ヒドロキシジェピロン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
HU228963B1 (en) 2013-07-29
CZ20022137A3 (cs) 2003-03-12
NO20022954L (no) 2002-06-19
CA2395458A1 (en) 2001-06-28
NO20022954D0 (no) 2002-06-19
AU2268701A (en) 2001-07-03
ES2241683T3 (es) 2005-11-01
IL150222A0 (en) 2002-12-01
NZ519554A (en) 2005-01-28
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
RU2282448C2 (ru) 2006-08-27
IL150222A (en) 2009-09-22
KR100602976B1 (ko) 2006-07-20
AU776409B2 (en) 2004-09-09
JP2004500362A (ja) 2004-01-08
CZ300429B6 (cs) 2009-05-20
PL364936A1 (en) 2004-12-27
DE60019968D1 (de) 2005-06-09
JP4236407B2 (ja) 2009-03-11
KR20020082470A (ko) 2002-10-31
HUP0301831A2 (hu) 2003-09-29
US6534507B1 (en) 2003-03-18
DE60019968T2 (de) 2006-02-02
NO323304B1 (no) 2007-03-05
CN1411375A (zh) 2003-04-16
WO2001045687A3 (en) 2002-04-25
RU2002119400A (ru) 2004-01-27
WO2001045687A2 (en) 2001-06-28
ATE294572T1 (de) 2005-05-15
EP1242061A2 (en) 2002-09-25
EP1242061B1 (en) 2005-05-04
CA2395458C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
GR3022459T3 (en) Quinuclidine derivative as substance p antagonist.
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
NZ514574A (en) Novel method of treatment
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
MY126555A (en) Oral pharmaceutical extended release dosage form
EP1258245A3 (en) Accelerated release composition containing bromocriptine
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
AU3850600A (en) Dalda analogs and their use
EP1539136A4 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
MY106661A (en) Therapeutic agent
MXPA02006146A (es) Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.
DE50211929D1 (en) Pyrimidinderivate
HK1024631A1 (en) Use of (+) mefloquine for the treatment of malaria
IL143985A0 (en) New use of melagatran
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
MY143571A (en) Eplerenone crystalline form
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
YU46302A (sh) Supstituisani piroli
MY133438A (en) Morpholinobenzamide salts
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
CA2392902A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents

Legal Events

Date Code Title Description
FG Grant or registration